1.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EFC10145, EudraCT 2007-003592-39, NCT00699517
|
|
2.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EFC10259, 2010-019384-11, U1111-1115-3677, NCT01263886
|
|
3.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TCD10620, EudraCT: 2007-006676-11, NCT00719524
|
|
4.
|
Phase: Phase I Type: Treatment Status: Completed Age: 20 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: TED10967, NCT00968916
|
|
5.
|
Phase: Phase I Type: Treatment Status: Completed Age: 20 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: TCD11088, NCT01021150
|
|
6.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BEX6587, 2008-007824-24, NCT01063946
|
|
7.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 20 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: TCD11089, U1111-1116-5905, NCT01095302
|
|
8.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 20 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: TCD11270, U1111-1115-2568, NCT01293630
|